[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Beta Nerve Growth Factor (Beta NGF or NGF) - Drugs in Development, 2021

March 2021 | 63 pages | ID: B1E4A087BDF9EN
Global Markets Direct

US$ 3,500.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Beta Nerve Growth Factor (Beta NGF or NGF) - Drugs in Development, 2021

SUMMARY

Beta Nerve Growth Factor (Beta NGF or NGF) pipeline Target constitutes close to 11 molecules. The latest report Beta Nerve Growth Factor - Drugs in Development, 2021, outlays comprehensive information on the Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Beta Nerve Growth Factor (Beta NGF or NGF) - Nerve growth factor is a neurotrophic factor involved in the regulation of growth, maintenance, proliferation, and survival of certain target neurons. It inhibits metalloproteinase dependent proteolysis of platelet glycoprotein VI. The molecules developed by companies in Pre-Registration, Phase III, Phase II, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 3, 1, 4 and 1 respectively.

Report covers products from therapy areas Central Nervous System, Cardiovascular, Ophthalmology, Dermatology, Hematological Disorders and Immunology which include indications Pain, Osteoarthritis Pain, Cancer Pain, Amyotrophic Lateral Sclerosis, Cardiac Arrest, Diabetic Neuropathic Pain, Glaucoma, Keratitis, Low Back Pain, Lung Transplant Rejection, Myocardial Infarction, Optic Nerve Injury, Parkinson's Disease, Peripheral Nerve Injury, Post-Operative Pain, Pressure Ulcers, Retinitis Pigmentosa (Retinitis), Sicca Syndrome (Sjogren) and Sickle Cell Disease.

Furthermore, this report also reviews key players involved in Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape for Beta Nerve Growth Factor (Beta NGF or NGF)
  • The report reviews Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics
REASONS TO BUY
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Beta Nerve Growth Factor (Beta NGF or NGF)Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Beta Nerve Growth Factor (Beta NGF or NGF) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Beta Nerve Growth Factor (Beta NGF or NGF) - Overview
Beta Nerve Growth Factor (Beta NGF or NGF) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Beta Nerve Growth Factor (Beta NGF or NGF) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Beta Nerve Growth Factor (Beta NGF or NGF) - Companies Involved in Therapeutics Development
AstraZeneca Plc
Dartbio Pharmaceuticals Co Ltd
Fujimoto Pharmaceutical Corp
MimeTech Srl
Pfizer Inc
Regeneron Pharmaceuticals Inc
Serometrix LLC
Staidson BioPharma Inc
Zhuhai Trinomab Biotechnology Co Ltd
Beta Nerve Growth Factor (Beta NGF or NGF) - Drug Profiles
DS-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fasinumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate NGF for Diabetic Neuropathy and Peripheral Nerve Injury - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MEDI-7352 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit Nerve Growth Factor for Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MT-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RBM-004 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Activate NGF Beta for Optic Nerve Injury - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit NGF for Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tanezumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
udonitrectag - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Beta Nerve Growth Factor (Beta NGF or NGF) - Dormant Products
Beta Nerve Growth Factor (Beta NGF or NGF) - Discontinued Products
Beta Nerve Growth Factor (Beta NGF or NGF) - Product Development Milestones
Featured News & Press Releases
Mar 25, 2021: Joint FDA advisory committee votes on application for tanezumab for the treatment of osteoarthritis pain
Jan 01, 2021: Congratulations to DartsBio Pharmaceutical for analgesic DS002 injection approved for clinical trial by NMPA
Jun 19, 2020: New therapy reduces chronic low back pain in large international study
Jun 19, 2020: New therapy reduces chronic low back pain in large international study
Mar 02, 2020: U.S. FDA accepts regulatory submission for Tanezumab, a potential first-in-class treatment for patients with chronic pain due to moderate-to-severe osteoarthritis
Jul 10, 2019: Drug shows benefit for osteoarthritis patients
Apr 23, 2019: Pfizer and Lilly report mixed results from trial of tanezumab
Feb 20, 2019: Pfizer-Lilly’s tanezumab reduces chronic low back pain in trial
Jan 29, 2019: Pfizer and Lilly announce top-line results from second phase 3 study of Tanezumab in osteoarthritis pain
Dec 05, 2018: Recordati receives orphan drug designation for its investigational treatment for neurotrophic keratitis
Oct 24, 2018: Pfizer and Eli Lilly report positive Phase III tanezumab trial results
Aug 17, 2018: Fasinumab Phase III osteoarthritis trial meets endpoints
Jul 20, 2018: Pfizer and Eli Lilly report positive results from Phase III tanezumab
Aug 17, 2017: Notice of the Start of a Japanese Phase 2/3 Clinical Study of the Anti-NGF Antibody MT-5547 in Osteoarthritis
Jun 13, 2017: Pfizer and Lilly Receive FDA Fast Track Designation for Tanezumab
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indication, 2021
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by AstraZeneca Plc, 2021
Pipeline by Dartbio Pharmaceuticals Co Ltd, 2021
Pipeline by Fujimoto Pharmaceutical Corp, 2021
Pipeline by MimeTech Srl, 2021
Pipeline by Pfizer Inc, 2021
Pipeline by Regeneron Pharmaceuticals Inc, 2021
Pipeline by Serometrix LLC, 2021
Pipeline by Staidson BioPharma Inc, 2021
Pipeline by Zhuhai Trinomab Biotechnology Co Ltd, 2021
Dormant Products, 2021
Dormant Products, 2021 (Contd..1)
Discontinued Products, 2021

LIST OF FIGURES

Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021


More Publications